These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38926964)

  • 21. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
    Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P
    Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
    Geirnaert M; Howarth J; Martin K; Ricard C; Streilein S; Wasney D; Dao V; Kotb R; Rimmer E; Minuk L
    J Oncol Pharm Pract; 2021 Jun; 27(4):907-910. PubMed ID: 33108988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye.
    Tekinalp A; Gedük A; Akdeniz A; Terzi Demirsoy E; Gürsoy V; Aslaner Ak M; Bağcı M; Seçilmiş S; Keklik Karadağ F; Oruç Uysal A; Doğan A; Demircioğlu S; Erol HA; Aslan C; Özkalemkaş F; Ertop Ş; Dağlı M; Dal MS; Saydam G; Merter M; Ural C; Çeneli Ö
    Turk J Haematol; 2023 Dec; 40(4):242-250. PubMed ID: 37961952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [No Abstract]   [Full Text] [Related]  

  • 26. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
    Hoylman E; Brown A; Perissinotti AJ; Marini BL; Pianko M; Ye JC; Campagnaro E; Nachar VR
    Leuk Lymphoma; 2020 Mar; 61(3):691-698. PubMed ID: 31739729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study.
    Kumar L; Melinkeri S; Ganesan P; Kumar J; Biswas G; Kilara N; Pathalingappa H; Prasad S; Jain M; Mishra SK; Prasad S; Boyella PK; Sahoo RK; Bondarde S; Shah S; Rege M; Deb U; Korde T; Dixit J
    Future Oncol; 2024 Feb; 20(4):191-205. PubMed ID: 38116642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
    Ailawadhi S; Cheng M; Cherepanov D; DerSarkissian M; Stull DM; Hilts A; Chun J; Duh MS; Sanchez L
    Curr Probl Cancer; 2024 Jun; 50():101078. PubMed ID: 38547609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
    Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
    Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
    [No Abstract]   [Full Text] [Related]  

  • 30. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
    Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
    Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
    Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
    Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
    Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
    N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
    Jing H; Yang L; Qi J; Qiu L; Fu C; Li J; Yang M; Qi M; Fan N; Ji J; Lu J; Li Y; Jin J
    Ann Hematol; 2022 Dec; 101(12):2679-2690. PubMed ID: 36301338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
    Stork M; Spicka I; Radocha J; Minarik J; Jelinek T; Jungova A; Pavlicek P; Pospisilova L; Sedlak F; Straub J; Pika T; Knechtova Z; Fidrichova A; Boichuk I; Sevcikova S; Maisnar V; Hajek R; Pour L
    Ann Hematol; 2023 Jun; 102(6):1501-1511. PubMed ID: 37088816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
    Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
    Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
    Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
    Minarik J; Pour L; Maisnar V; Spicka I; Jungova A; Jelinek T; Brozova L; Krhovska P; Scudla V; Hajek R
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Sep; 163(3):279-283. PubMed ID: 30397362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.